Delivery Order SPE2DP20D0002-SPE2DP24F6266

Award Date 7/19/24
Potential Completion Date 7/30/24
Potential Value $159K
Federal Agency
Medical Supply Chain
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. government agency Defense Logistics Agency (DLA) Troop Support Medical awarded a $158,804.73 firm-fixed-price delivery order contract to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. This delivery order is part of a larger contract vehicle, and Teva has received multiple prior delivery orders for this vaccine to support military immunization programs. Teva also holds several significant Indefinite...
This federal contract award, valued at $158,804.73, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of Adenovirus Type 4 vaccines to support military immunization programs. Teva Pharmaceuticals USA, Inc. has a history of providing critical drug products, such as vaccines, antiviral medications, respiratory treatments, and multiple sclerosis drugs, to...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $317,609.46 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Teva with DLA Troop Support Medical for providing critical pharmaceuticals to support military immunization programs. Teva has also been awarded other significant...
This federal contract award, valued at $158,804.73, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a large, foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of Adenovirus Type 4 vaccines to support military immunization programs. This is a firm-fixed-price delivery order contract with an ultimate completion date of August 27, 2024. Teva Pharmaceuticals USA, Inc. has a long history of supplying...
This federal contract award, valued at $5,285,021.76, was issued by the Defense Logistics Agency (DLA) to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is a firm-fixed-price delivery order for the supply of Adenovirus Type 4 vaccine, which supports military immunization programs. The award has an ultimate completion date of February 4, 2025. Teva Pharmaceuticals USA, Inc. is a major supplier of critical pharmaceutical products to various...
The federal contract award, with ID SPE2DP20D0002|SPE2DP24F6264, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract, valued at $476,414.19, is for the delivery of Adenovirus Type 4 vaccine, a critical product supporting military immunization programs. This is a delivery order contract with a firm-fixed price pricing type, and the ultimate completion date is July 30,...
The U.S. Defense Logistics Agency (DLA) awarded Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, a $317,609.46 Delivery Order contract for the supply of Adenovirus Type 4 vaccines. This order falls under DLA Troop Support Medical's larger portfolio of contracts supporting military immunization programs. The contract has a firm fixed-price, with a completion date of June 25, 2024. Teva Pharmaceuticals USA, Inc. is a major supplier of critical drugs and...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the supply of Adenovirus Type 4 vaccine, a critical product for military immunization programs. The $158,804.73 firm-fixed-price contract has a period of performance through March 26, 2024. Teva Pharmaceuticals USA, Inc. has been awarded numerous prime federal contracts and delivery orders from...
This federal contract award, valued at $990,941.58, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is a delivery order for the supply of Adenovirus Type 4 vaccine, a critical medical product that supports military immunization programs. The contract is a firm-fixed-price arrangement with a period of performance through March 25, 2025. Teva Pharmaceuticals USA, Inc....
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned pharmaceutical manufacturer. The contract is for the delivery of Adenovirus Type 4 vaccine, which supports military immunization programs. The firm-fixed-price delivery order has a ceiling value of $660,627.72 and a period of performance through March 25, 2025. This award is not set-aside and represents one of Teva's many unrestricted contract awards...
  • SPE2DP20D0002
    Indefinite Delivery Contract
  • SPE2DP20D0002-SPE2DP24F6266
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The $158,804.73 fixed-price delivery order is for the supply of Adenovirus Type 4 vaccine, which supports military immunization programs. Teva Pharmaceuticals USA, Inc. holds multiple Indefinite Delivery Contracts (IDCs) with federal agencies, including a $64,352,514.80 IDC with the Department of Veterans Affairs (VA) for glatiramer acetate injections, a $109,085,460 IDC with the VA for Albuterol HFA inhalers, and a $5,687,207.30 IDC with the DLA for Levalbuterol HCL Solution. These long-term contracts demonstrate Teva's critical role in supplying essential pharmaceutical products to various federal healthcare programs, including the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. The contract award does not have a set-aside designation, as Teva competes as a large business in unrestricted solicitations.

Generated 10/18/24, 9:20 AM